# Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Page: https://stenobird.com/podcast/the-imid-forum-981476/discussing-axspa-adalimumab-dosing-and-uveitis-recurrence-in-patients-with-ankylosing-spondylitis
Text version: https://stenobird.com/podcast/the-imid-forum-981476/discussing-axspa-adalimumab-dosing-and-uveitis-recurrence-in-patients-with-ankylosing-spondylitis.md
Podcast: [The IMID Forum](https://stenobird.com/podcast/the-imid-forum-981476)
Published: 2025-11-13T09:04:18+00:00
Episode link: https://soundcloud.com/imidforum/discussing-axspa-adalimumab-dosing-and-uveitis-recurrence-in-patients-with-ankylosing-spondylitis
Audio file: https://feeds.soundcloud.com/stream/2211731435-imidforum-discussing-axspa-adalimumab-dosing-and-uveitis-recurrence-in-patients-with-ankylosing-spondylitis.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-axspa-adalimumab-dosing-and-uveitis-recurrence-in-patients-with-ankylosing-spondylitis
Duration seconds: 877

## Resource

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-axspa-adalimumab-dosing-and-uveitis-recurrence-in-patients-with-ankylosing-spondylitis/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-axspa-adalimumab-dosing-and-uveitis-recurrence-in-patients-with-ankylosing-spondylitis.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.